Physician profile
Veronica Cannon
NPI 1689080384
$439.87
in general payments reported to CMS, 2019-2025
12 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.04 · 2022: $30.17 · 2023: $93.62 · 2024: $88.03 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $352.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $130.48 | 2024-2025 | Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.59 | 2023-2025 | Caplyta |
| Gilead Sciences, INC. | $38.56 | 2021 | |
| Supernus Pharmaceuticals, INC. | $29.07 | 2024-2025 | Qelbree |
| Axsome Therapeutics, INC. | $25.19 | 2024 | Auvelity |
| Lilly USA, LLC | $23.01 | 2025 | Mounjaro |
| Glaxosmithkline, LLC. | $18.90 | 2023 | Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $18.48 | 2021 | |
| Abbvie INC. | $17.76 | 2022 | |
| Alkermes, INC. | $17.14 | 2023 | Lybalvi |
| Neurocrine Biosciences, INC. | $15.28 | 2023 | Ingrezza |
| Novo Nordisk INC | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Cannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.